Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics

Silvia Stacchiotti(Fondazione IRCCS Istituto Nazionale dei Tumori), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Tiziana Negri(Fondazione IRCCS Istituto Nazionale dei Tumori), M. Libertini(Molecular Oncology (United States)), Denis Cominetti(Fondazione IRCCS Istituto Nazionale dei Tumori), A. Messina(Fondazione IRCCS Istituto Nazionale dei Tumori), Fabio Bozzi(Fondazione IRCCS Istituto Nazionale dei Tumori), Elena Palassini(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Nadia Zaffaroni(Fondazione IRCCS Istituto Nazionale dei Tumori), Carlo Morosi(Fondazione IRCCS Istituto Nazionale dei Tumori), M. Tortoreto(Molecular Oncology (United States)), Elena Tamborini(National Cancer Institute), S. Pilotti(Molecular Oncology (United States))
Clinical Cancer Research
July 26, 2013
10.1158/1078-0432.ccr-13-0776
Cited by 80

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Isolation and <i>In vitro</i> Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties
|Cancer Research|2005|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978